Literature DB >> 30520145

Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.

S C Gordon1, M Abudu1, P Zancanaro1, J M Ko2, D Rosmarin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30520145     DOI： 10.1111/jdv.15383

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

Review 1.  Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Authors:  Ana M Montilla; Francisco Gómez-García; Pedro J Gómez-Arias; Jesús Gay-Mimbrera; Jorge Hernández-Parada; Beatriz Isla-Tejera; Juan Ruano
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-13

Review 2.  Emerging Topical and Systemic JAK Inhibitors in Dermatology.

Authors:  Farzan Solimani; Katharina Meier; Kamran Ghoreschi
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

3.  Effectiveness of Oral Tofacitinib Dose Tapering in a Case of Alopecia Areata Universalis.

Authors:  Mariana Esteves; Sofia Lopes; Filomena Azevedo; Ana Pedrosa
Journal:  Skin Appendage Disord       Date:  2020-09-30

4.  Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.

Authors:  Özge Aşkın; Defne Özkoca; Tuğba Kevser Uzunçakmak; Server Serdaroğlu
Journal:  Dermatol Ther       Date:  2021-01-18       Impact factor: 3.858
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.